article thumbnail

Vedolizumab Outperformed Infliximab in Real-World Outcomes

Physician's Weekly

The following is a summary of “Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment—real world comparative effectiveness from German claims data,” published in the June 2025 issue of BMC Gastroenterology by Dignass et al.

article thumbnail

Personalized medicine in a community health system: the Endeavor Health experience [Dissemination and implementation research]

Annals of Family Medicine

In 2014, Endeavor Health (formerly NorthShore University HealthSystem) launched the Center for Personalized Medicine to catalyze the delivery of personalized medicine. Context: Genomic and personalized medicine implementation efforts have largely centered on specialty care in tertiary health systems.

Community 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

From GRP to SIUU – the Evolution of FDA Guidance on Off-Label Dissemination of Scientific Information

FDA Law Blog

Previous iterations of this guidance from 2009 and 2014 (blogged on here and here ) were known as Good Reprint Practices (GRP). The SIUU Guidance, which supersedes the 2014 Draft GRP Guidance, is not substantially different in that regard and contains similar information as to the types of disclosures previously recommended.

Clinic 64
article thumbnail

A Final LDT Rule in April!? Will FDA be prepared?

FDA Law Blog

14] Thus, while the Third-Party Review Program is not well‑utilized generally, it is not utilized at all by the in vitro diagnostic industry. 2, 2014), [link]. [12] First, FDA notes that the Agency is “currently working to enhance our Third-Party Review Program, which was reauthorized under MDUFA V.” [10] 31, 2023), [link]. [10]

IT 69
article thumbnail

FDA’s Accelerated Approval of Biogen’s Aduhelm for Alzheimer’s: A Sign of Applying the Emergency Use Standard Beyond COVID?

FDA Law Blog

Subpart H) pathway in 2014, then issued it as final guidance in January 2019. Both Dr. Dunn, in his memo to the PCNS Advisory Committee members, and Dr. Cavazzoni, in her statement, emphasized the utility of Accelerated Approval in devastating conditions where the needs for treatments are urgent. What do we mean?

Clinic 98
article thumbnail

RCT of Default Inpatient PC Consults: Kate Courtright & Scott Halpern

GeriPal

Kate: No, it’s a tough answer in part because, as Scott mentioned, this was being implemented somewhere in the 2014/15 range after funding and building and that pilot year. Eric: Utilization, utilization, utilization. Kate: This is where maybe that bottle of alcohol’s needed. laughter] Eric: Enough said.

article thumbnail

Sweet! A Metabolic Disorders focused podcast episode

PEMBlog

She did her MD/PhD at Columbia University, where she investigated the diagnostic utility of exome sequencing for kidney disease. You can contact her via email at egroopman@childrensnational.org. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: [link] Rice GM, Steiner RD. Pediatr Rev. 2016 Jan;37(1):3-15; quiz 16-7, 47.